Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The HDAC Inhibitor Sodium Butyrate Prevents Allergic Rhinitis and Alters lncRNA and mRNA Expression Profiles in the Nasal Mucosa of Mice

ABSTRACT: Our previous research confirmed that histone deacetylase inhibitor sodium butyrate (NaB), delivered intranasally, has exhibits therapeutic effects on a mouse model of allergic rhinitis (AR). However, whether it is effective on AR when administered orally and prophylactically, as well as its potential effects on gene expression, remained unknown. Methods: In this study, we investigated the preventive effect of NaB on AR when added to the diet of newly weaned mice and evaluated changes in lncRNA and mRNA expression profiles in the nasal mucosa. Mice were randomly divided into three groups as follows: C group (control group, no treatment), AR group (treated with ovalbumin [OVA]), and NaB+AR group (treated with both OVA and NaB). The NaB+AR group was given NaB in their feed (30 g/kg), whereas the other two groups were fed normal feed from 3 weeks to 6 weeks of age. At 7 weeks of age, OVA administration was initiated to induce AR in the AR and NaB+AR groups. Then, behavioral assessments, western blotting, and gene analysis were performed.

ORGANISM(S): Mus musculus

PROVIDER: GSE140454 | GEO | 2020/03/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Allergen exposure was thought to play a critical role in the etiology of AR. And allergen avoidance, the practice of avoiding exposure to allergens, has been generally advised as the management of AR. However, the effect is uncertain and the underlying mechanism is far from known. We used gene expression microarrays to identify genes differentially regulated by allergen avoidance in allergic rhinitis mouse model. Affymetrix Mouse Gene 1.0 ST arrays were used to identify the expression profiling of nasal mucosa in three groups of mice: (1) mice sensitized and challenged with saline (control group); (2) mice sensitized and challenged with ovalbumin (OVA) and sacrificed 2 hours after the last challenge (OVA group); (3) mice sensitized and challenged with OVA and sacrificed 4 weeks after the last challenge (4w-after group).

2013-11-28 | E-GEOD-52804 | biostudies-arrayexpress

The differential expressed mRNAs in spleen B cells between control(normal)，PBS treated or SJMHE1(Schistosoma japonicum-derived peptide) treated OVA-induced allergic rhinitis mice.

Project description:In order to explore the molecular mechanism of SJMHE1 intervention in allergic rhinitis, an OVA-induced allergic rhinitis model was established and intervened by subcutaneous injection of PBS and SJMHE1. Then a global RNA sequencing of mouse spleen B cells from the control, PBS, and SJMHE1 groups were performed.

2023-04-30 | GSE229347 | GEO

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

Project description:To explore the impact of nasal commensal viruses on the onset and progression of allergic rhinitis, We used single cell RNA sequencing (scRNA-seq) to analyze the diversity of CD45+ cells in the nasal mucosa of mice treated with Vehicle, Ribavirin, Vehicle-OVA, or Ribavirin-OVA.

2024-08-21 | GSE266238 | GEO

Effects of anticholinergic agent on miRNAs profile and transcriptome in murine model of allergic rhinitis

Project description:Purpose: Ipratropium bromide (IB) is able to ameliorate symptoms of allergic rhinitis (AR) by neuroimmunologic mechanism. We intended to explorer whether IB induced effect through modulating specific alteration of miRNA profiling or not. Methods: Nasal sRNAs (miRNAs) profiles of control mice and OVA-induced AR mice that were pre-treated with IB or normal saline before intranasal OVA challenge for 2 or 4 weeks were generated by high-throughput sequencing using Illumina Hiseq 2000.Raw data for sRNA (miRNA) profiles were processed to obtain corresponding clean data which were mapped to reference sequence(mm10) by TopHat(v2.0.9).The expression levels for these resulting mapped miRNAs were estimated by TPM (transcript per million),afterwards, the differentially expressed miRNAs were identified, and the candidate allergic-related miRNAs were further determined by RT-qPCR. Results: Using an optimized data analysis workflow,our data showed that in nasal mucosa of allergic mice with ipratropium bromide (IB) treatment 87 miRNAs are differentially expressed whereas in the nasal mucosa of non-allergic mice 113 miRNAs are differentially expressed, when compared with allergic mice treated with normal saline.IB treatment significantly up-regulated the levels of mmu-miR-124-3p/5p, -133b-5p, -133a-3p/5p, -384-3p, -181a-5p, -378a-5p, -3071-5p. RT-qPCR data further validated these miRNAs expression. Conclusions: Our study represents the detailed analysis of nasal mucosa miRNAs profiles of OVA-induced allergic mice treated with IB, generated by RNA-seq technology. Moreover, IB treatment orchestrated expression of allergic immune-related miRNAs of nasal mucosa in allergic mice, which may associate with ameliorated nasal allergic symptoms

2018-07-31 | GSE92975 | GEO

Lung transcriptome profile in healthy and OVA-sensitized/challenged mice fed a diet supplemented with or without Cap or ODNcap

Project description:CpG-oligodeoxynucleotides (CpG-ODNs) constitute an attractive alternative for asthma treatment. We found that free feeding of an ODNcap (a CpG-ODN-embedded particle) -containing feed (ODNcap-F) prophylactically attenuates allergic airway inflammation, hyperresponsiveness, and goblet cell hyperplasia in an ovalbumin (OVA) -induced asthma model. To seek the suppressive mechanism of action of ODNcap-F in OVA-induced airway insults, we analyzed the lung transcriptome using DNA microarray analysis.

2021-09-29 | GSE180287 | GEO

Systematic transcriptome and molecular docking analyses reveals that Cirsium japonicum mitigates allergic nasal inflammation through regulation of NRF2-mediated mucin production in an allergic rhinitis mouse model

Project description:Allergic rhinitis (AR) is a typical allergic disease mediated by immunoglobulin E (IgE), which greatly affects the quality of life and is more sensitive to change of seasons due to various nasal symptoms. AR worsening symptoms can lead to more dangerous diseases, there is an urgent need to develop safe and effective treatments. Cirsium japonicum (CSJ) is a plant that has been used in traditional medicine due to its various efficacy and safety; so far, the effects and major mechanisms of CSJ on AR have not been reported. Therefore, the purpose of this study was to investigate the possible targets of CSJ for AR treatment and its underlying mechanisms. An ovalbumin (OVA)-induced AR mouse model was established and the therapeutic effects of CSJ were evaluated. CSJ reduced the production level of OVA-specific IgE, histamine, and Th2 cytokines in serum, and significantly alleviated the typical symptoms of AR and the level of inflammation in the nasal mucosa. In addition, we used transcriptome analysis in AR models to identify that O-linked glycosylation of mucins, MUC5AC, and NRF2 are key targets for CSJ related to AR. Then, we identified the active ingredients of CSJ for AR, and verified that the active core compounds of CSJ, cryptochromogenic acid and cirsimarin, could bind closely to potential key targets, NRF2-KEAP1, and MUC5AC using molecular docking analysis. In conclusion, our results suggest that CSJ may be a more effective candidate drug for the treatment of AR with dual function to regulate both NRF2 pathway and MUC5AC expression.

2024-10-23 | GSE246623 | GEO

2013-11-28 | GSE52804 | GEO

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

Project description:For analyzing the exploratory nasal commensal viruses, we performed the metatranscriptomic analysis of the nose swabs from the enrolled AR patients both before and after treatments, as well as sequenced the nose swabs from a set of healthy volunteers without AR history.Simultaneously, to assess the expression of interferon-stimulated genes in patients with allergic rhinitis, we analyzed the gene expression of host reads.

2024-08-21 | GSE275114 | GEO

Dendritic cells mediated by small extracellular vesicles derived from MSCs attenuated the ILC2 activity in patients with allergic rhinitis

Project description:Mesenchymal stromal cells-derived small extracellular vesicles (MSC-sEVs) have recently attracted considerable attention because of their therapeutic potential in various immune diseases. We previously reported that MSC-sEVs could exert immunomodulatory roles in allergic airway inflammation by regulating group 2 innate lymphoid cell (ILC2) and dendritic cell (DC) functions. Therefore, this study aimed to investigate the therapeutic effects of MSC-sEVs on mature DC (mDC)-ILC2 interplay in allergic rhinitis (AR). Here, we isolated MSC-sEVs from induced pluripotent stem cells (iPSC)-MSCs using anion-exchange chromatography for the generation of sEV-mDCs. sEV-mDCs were co-cultured with peripheral blood mononuclear cells (PBMCs) from patients with AR or purified ILC2s. The levels of IL-13 and GATA3 in ILC2s were examined by flow cytometry. Bulk RNA-sequence for mDCs and sEV-mDCs was employed to further probe the potential mechanisms, which were then validated in the co-culture systems.

2023-06-27 | GSE229003 | GEO

Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses

Project description:To elucidate the potential role of commensal viruses in the etiology of AR, we performed a metagenomic analysis of nasal lavage fluid (NLF) to identify commensal viruses in the nose of mice colonizing in the specific pathogen-free (SPF) circumstances (Vehicle group). To evaluate the potential role of these commensal viruses, we reduced them in the nose of mice by administrating intranasal drops of broad-spectrum antiviral drug ribavirin daily, starting at 4-week-old and lasting for three weeks (Ribavirin group).

2024-08-21 | GSE271863 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data